PVLA NASDAQ
Palvella Therapeutics, Inc.
1W: -2.6%
1M: -11.3%
3M: +35.3%
YTD: +15.6%
1Y: +399.0%
$113.99
-1.93 (-1.66%)
Weekly Expected Move ±9.3%
$93
$104
$114
$125
$135
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (48)
Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
Palvella Therapeutics approved for transfer to Nasdaq Global Market
Palvella targets 2H 2026 NDA filing while outlining >$1B peak U.S. sales potential for QTORIN rapamycin in microcystic lymphatic malformations
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
Deltec Asset Management LLC Has $251,000 Stock Position in Palvella Therapeutics, Inc. $PVLA
Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
Analysts Set Palvella Therapeutics, Inc. (NASDAQ:PVLA) Price Target at $198.07
Equities Analysts Offer Predictions for PVLA FY2026 Earnings
What is HC Wainwright’s Forecast for PVLA FY2026 Earnings?
Q1 Earnings Forecast for PVLA Issued By HC Wainwright
Palvella Therapeutics GAAP EPS of -$3.71 misses by $0.19
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
Earnings Scheduled For March 31, 2026
Quant snapshot: J. Jill, AngioDynamics leads strong buys as INmune Bio, Terrestrial Energy lag
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
Palvella Stock Up 340% as Insider Sells Shares. Here's What the Move Does (And Does Not) Signal
Director Buys $500,000 Worth of Palvella Therapeutics Shares After Phase 3 Win
Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services
Kathleen Goin Sells 4,302 Shares of Palvella Therapeutics (NASDAQ:PVLA) Stock
Palvella Therapeutics Announces Issuance of European Patent Covering Anhydrous Compositions of Rapamycin
Apis Capital Advisors LLC Makes New Investment in Palvella Therapeutics, Inc. $PVLA
Analysts Set Palvella Therapeutics, Inc. (NASDAQ:PVLA) Price Target at $184.87
Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up Following Analyst Upgrade
Palvella Therapeutics stock rises on $200M share offering
Palvella Therapeutics Announces Pricing of Upsized Public Offering
Palvella Therapeutics launches $150M public stock offering
Palvella surges on late-stage trial win for lead asset
Palvella Therapeutics Announces Proposed Public Offering
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations
Analysts Set Palvella Therapeutics, Inc. (NASDAQ:PVLA) Price Target at $158.69
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives $158.69 Consensus Price Target from Analysts
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Short Interest Up 60.9% in December
Palvella Therapeutics Provides Corporate Update and 2026 Outlook: Advancing a Late Clinical-Stage Pipeline and Platform to Address Multiple Serious, Rare Skin Diseases and Vascular Malformations with No FDA-Approved Therapies
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs
Palvella Therapeutics: Phase 2 Success De-Risks 2026 Catalyst
Palvella Therapeutics Granted FDA Fast Track Designation for QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Angiokeratomas
Palvella: 73% Improved In Phase 2 Study Of Skin Condition Treatment
Palvella Therapeutics Announces Positive Topline Results from Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations, a Serious, Rare Genetic Disease with No FDA-approved Therapies